Novo Cuts Price of Ozempic in Half for Cash Buyers

Market Dynamics - Novo Nordisk is aiming to regain market share from Eli Lilly in the GLP-1 market [2][10] - The obesity market is projected to reach $95 billion by 2030 [11] - Novo Nordisk is competing with compounders who offer lower-priced alternatives [4][5] Strategic Moves - Novo Nordisk is launching a cash pay version of Ozempic and expanding partnerships to increase drug accessibility [3][9] - Novo Nordisk is lowering the price of Ozempic for cash-paying patients [3][4] - Novo Nordisk already launched cash pay at cheaper Wegovy back in March for $500 per month [8] Financial Implications - The cost of Ozempic for cash-paying patients is $500 per month at the maximum dose of 2 milligrams per injection, which is $65 per milligram [4] - Compounders are offering alternatives at prices like $119.90 [5]